A new generation of melanoma researchers
15 February 2018
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
James Wilmott is part of the new generation of melanoma researchers, and was drawn to Melanoma Institute Australia by the direct link between clinical research and patient care. He knew this was an area in which he could really make a difference.
“Being a scientist, you don’t often see patients in your day to day work,” he explains. “I thought by working at Melanoma Institute Australia, where it brings together clinical research and basic science, I could see patients as well as do the cutting edge research.”
Dr Wilmott’s work focuses on why 15 to 39 year olds are being diagnosed with melanoma at a higher rate than any other cancer. Early results of whole genome sequencing of tumours from these patients show 90% of all mutations in a 16 year old patient are caused by the sun – a surprising result given the young age of the patient.
“It is surprising because it looks similar to what we see in adults… and the accumulation over a lifetime,” Dr Wilmott says. “They must have some sort of genetic abnormalities that make them more susceptible to UV damage. If we can pinpoint the genes that make them susceptible, and then find them in other young patients, we can target them with preventative measures to prevent them from getting melanoma in the first place.
“It’s an exciting time to be involved in melanoma research. We’re making great inroads into melanoma care,” he said.
James’ is the latest in a series of emotive videos launched by Melanoma Institute Australia, showing the impact of melanoma on everyday Australians. Watch his story here and join him in the fight against melanoma by signing up for a Melanoma March event near you.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.